MedPath

Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.

Conditions
Intrauterine Growth Retardation
Stillbirth
Infant, Small for Gestational Age
Interventions
Other: Antenatal identification of fetal growth restriction
Registration Number
NCT01995968
Lead Sponsor
University Hospital, Grenoble
Brief Summary

The main objective is to assess the role of antenatal detection of fetal growth restriction (FGR) on stillbirth, by a case-control study in a population-based sample of small for gestational age (SGA) livebirths and stillbirths in 3 French counties (Isère, Savoie and Haute-Savoie). SGA births will be defined as a birthweight below the 10th percentile of French customised birth weight curves.

Our secondary objectives are

* to identify determinants of antenatal detection of FGR among a representative sample of SGA births, with a special interest in the definition of FGR. Our hypothesis is that births who are SGA by customised birthweight curves and non-SGA by population birthweight curves, are not detected antenatally, despite the current strategy including the use of umbilical Doppler.

* to analyse prenatal care of a subsample of SGA stillbirths with and without detection of FGR by a confidential enquiry.

Detailed Description

Stillbirths will be identified by the RHEOP (Registre des Handicaps de l'Enfant et Observatoire Périnatal).

The RHEOP was created in 1988 in the Isère district in the Rhône-Alpes region of France. The area covered by the registry was enlarged to include two contiguous districts in 2005 (Savoie and Haute-Savoie). This registry includes all cases of childhood disability as well as all stillbirths to residents in these districts. Its objective is to monitor the trends in stillbirth and chid disability, and to identify conditions associated with these events. The three participating districts constitute a population-based sample of 30 000 births per year. The RHEOP registry uses the WHO definition of a stillbirth, i.e., "the birth of a baby with a birth weight of 500 g or 22 or more completed weeks of gestation who died before or during labor and birth". Its completeness is checked by matching its database with three data sources : results of placental examination and fetal autopsy, adjacent register of fetal anomalies, and regional reference center for prenatal diagnosis.

Stillbirths are identified in maternity hospitals thanks to collaborating midwifes and routinely collected data. Several specific investigators, who are trained nurses, midwives or physicians, complete a standardized form based on the medical record for each case.

For the purpose of the project, additional data will be collected allowing to describe prenatal care including ultrasound and Doppler examinations, and obstetrical management. Healthcare professionals (GP, midwife, obstetricians and gynecologists) will be solicited if data are missing in maternity medical records. SGA stillbirths in 2012 and 2013 will be included.

Consecutive SGA livebirths to residents in Isère, Savoie and Haute-Savoie, will be identified by the same way. Two months (probably october and november 2013)are approximately needed to record the sample size of controls.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
480
Inclusion Criteria

Births:

  • Stillbirths (antepartum or intrapartum fetal death) (=Cases) or livebirths (=Controls)
  • at or after 24 completed weeks of gestational age
  • singletons
  • to mothers residents in 1 of the 3 districts (Isère, Savoie, Haute-Savoie) of the RHEOP register
  • SGA: birthweight below the 10th percentile of French customised birthweight curves)
Exclusion Criteria
  • Fetal deaths with date of death estimated being older than date of birth by at least 1 week
  • Lethal congenital anomalies

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SGA stillbirths (Cases)Antenatal identification of fetal growth restrictionStillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
SGA livebirths (Controls)Antenatal identification of fetal growth restrictionLivebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
Primary Outcome Measures
NameTimeMethod
Rate of antenatal detection of FGRbaseline

Crude and adjusted OR of stillbirth according to antenatal detection of FGR

Secondary Outcome Measures
NameTimeMethod
fetal deaths of SGA newborns with and without antenatal detection of FGRbaseline
Factors associated with lack of antenatal detection of FGR in a representative sample of SGA birthsbaseline

Crude and adjusted OR and 95% confidence intervals

Trial Locations

Locations (21)

Clinique Générale Annecy

🇫🇷

Annecy, France

CH Albertville-Moutiers

🇫🇷

Albertville, France

Polyclinique de Savoie Annemasse

🇫🇷

Annemasse, France

CH Annecy

🇫🇷

Annecy, France

CHI Annemasse Bonneville

🇫🇷

Bonneville, France

Centre Hospitalier Bourgoin Jallieu

🇫🇷

Bourgoin-Jallieu, France

CH Bourg Saint Maurice

🇫🇷

Bourg Saint Maurice, France

Clinique Saint Vincent de Paul Bourgoin Jallieu

🇫🇷

Bourgoin Jallieu, France

Hopital Femme Mere Enfant

🇫🇷

Bron, France

CH Chambéry

🇫🇷

Chambéry, France

Clinique des Cèdres

🇫🇷

Echirolles, France

Clinique Mutualiste Eaux Claires

🇫🇷

Grenoble, France

Chu Grenoble

🇫🇷

Grenoble, France

Hopital Croix rousse

🇫🇷

Lyon, France

Clinique Belledonne

🇫🇷

Saint Martin d Hères, France

CH Saint Jean de Maurienne

🇫🇷

Saint-Jean-de-Maurienne, France

CH Sud Léman Valserine

🇫🇷

Saint-Julien-en-Genevois, France

Hôpitaux du Mont Blanc

🇫🇷

Sallanches, France

Centre Hospitalier Vienne

🇫🇷

Vienne, France

Hôpitaux du Léman

🇫🇷

Thonon-les-Bains, France

Centre Hospitalier Voiron

🇫🇷

Voiron, France

© Copyright 2025. All Rights Reserved by MedPath